Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 36Neoplasm Metastasis 10Neoplasms 7Brain Neoplasms 4Triple Negative Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Malignant Solid Tumors 3Stomach Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Thrombocytosis 1Solid Tumor 1Salivary Gland Neoplasms 1Recurrence 1Rare Tumour 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neuroma, Acoustic 1Neurofibromatosis 2 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningioma 1Malignant Female Reproductive System Neoplasm 1

Interventions

Letrozole 6Radiotherapy 4Carboplatin 4atamestane 3Trastuzumab 3Toremifene 3Magnetic Resonance Spectroscopy 3Fulvestrant 3Docetaxel 3Cyclophosphamide 3Chemotherapy, Adjuvant 3Tamoxifen 2Paclitaxel 2Estrogen Receptor Modulators 2Capecitabine 2Aromatase Inhibitors 2repotrectinib 1proto-oncogene protein c-fes-fps 1palbociclib 1neratinib 1gallium 68 PSMA-11 1fluciclovine F-18 1entrectinib 1Zolpidem 1Vorinostat 1Vinorelbine 1Venlafaxine Hydrochloride 1Thiotepa 1Taxes 1Sugars 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Lobular × neratinib × Clear all
NCT05919108 2025-09-09

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
30 enrolled

Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡